Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Reverse total shoulder arthroplasty (RTSA) has become an established treatment for cuff arthropathy, severe osteoarthritis and in certain fracture cases. Due to the increasingly aging population, patients who have already exceeded their life-expectancy pose a significant challenge to the shoulder surgeon. Therefore, we wanted to investigate patient demographics, hospital stay length, complication rate functional outcome, patient reported outcome scores and mortality retrospectively for patients, who were older than 83 years at time of implantation of a RTSA.
This is a retrospective single institution study. All patients older than 83 years who received a reverse shoulder arthroplasty from 2008 until 2019 are included. Elective cases are compared to fracture cases (patient demographics, length of hospital stay, complication rate, functional outcome, patient reported outcome scores and mortality).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Elective cases | Patients, who received a RTSA for degenerative reasons like cuff arthropathy or osteoarthritis |
| |
| Fracture cases | Patients, who received a RTSA for a proximal humerus fracture |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Reverse Total Shoulder Arthroplasty (RTSA) | Procedure | Implantation of a Reverse Total Shoulder Arthroplasty |
|
| Measure | Description | Time Frame |
|---|---|---|
| Patient reported outcome score: ASES | American Shoulder and Elbow Society (ASES) Score | until august 2020 |
| Complication rate | postoperative complications requiring surgical intervention | until august 2020 |
| Quality adjusted life year (QALY) | The quality adjusted life year (QALY) ) is a well-established indicator of the life quality for the remaining years and was calculated as the years of life following the operation, multiplied by the utility value, for the current study, defined as the postoperative American Shoulder and Elbow Surgeons Shoulder Score (ASES) score (0-1 points) at last follow-up. | until august 2020 |
| Mortality | Survivership | until august 2020 |
| Patient reported outcome score: QuickDASH | Quick Disabilities of the arm, shoulder and hand (DASH) Score, | until august 2020 |
| Patient reported outcome score: VAS | Visual analog score (VAS) | until august 2020 |
| Measure | Description | Time Frame |
|---|---|---|
| Patient demographics | male/female ratio, age, BMI, ASA (American Society of Anesthesiologists) classification, hospital stay length, range of motion | at time of surgery |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients who have already exceeded their life-expectancy (83 years in Switzerland)
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mai Lan Dao Trong, MD | Bürgerspital Solothurn | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Bürgerspital Solothurn | Solothurn | 4500 | Switzerland |
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Date | Date Unknown |
|---|---|---|
| Release | Jun 13, 2021 | |
| Reset | Jul 2, 2021 | |
| Release | Aug 30, 2021 | |
| Reset | Sep 23, 2021 | |
| Release | Mar 1, 2022 | |
| Reset | May 17, 2022 | |
| Release | Sep 24, 2022 | |
| Reset | Aug 3, 2023 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Jun 13, 2021 | Jul 2, 2021 | |||
| Aug 30, 2021 |
Not provided
Not provided
Not provided
| Sep 23, 2021 |
| Mar 1, 2022 | May 17, 2022 |
| Sep 24, 2022 | Aug 3, 2023 |